We are live on ! Find out more
TCRX icon

TScan Therapeutics
TCRX

28 hedge funds and large institutions have $20.3M invested in TScan Therapeutics in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 3

37% more capital invested

Capital invested by funds: $14.8M → $20.3M (+$5.52M)

0.78% more ownership

Funds ownership: 50.26% → 51.04% (+0.78%)

0% more funds holding

Funds holding: 28 → 28 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

Holders
28
Holders Change
–
Holders Change %
0%
% of All Funds
0.45%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
3
Increased
9
Reduced
3
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
SAM
Simplify Asset Management
Nevada
+$1.3M
2
Morgan Stanley
Morgan Stanley
New York
+$212K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$73.1K
4
State Street
State Street
Massachusetts
+$25.2K
5
WPW
Waldron Private Wealth
Pennsylvania
+$23.7K

Top Sellers

1
TCM
Tang Capital Management
California
-$798K
2
Millennium Management
Millennium Management
New York
-$31K
3
Prudential Financial
Prudential Financial
New Jersey
-$20.9K
4
LPL Financial
LPL Financial
California
-$11.9K
5
TRCT
Tower Research Capital (TRC)
New York
-$5K
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$5.85M – – –
BlackRock
2
BlackRock
New York
$3.18M +$2.62K +1,104 +0.1%
DMC
3
Deer Management Company
New York
$2.62M – – –
AI
4
Alphabet Inc
California
$2.26M – – –
DF
5
DC Funds
Virginia
$1.32M – – –
Adage Capital Partners
6
Adage Capital Partners
Massachusetts
$1.16M – – –
SAM
7
Simplify Asset Management
Nevada
$1.15M +$1.3M +546,916 New
Vanguard Group
8
Vanguard Group
Pennsylvania
$623K +$73.1K +30,771 +12%
NM
9
Newtyn Management
New York
$497K +$16.1K +6,800 +3%
TCM
10
Tekla Capital Management
Massachusetts
$420K – – –
Morgan Stanley
11
Morgan Stanley
New York
$276K +$212K +89,144 +211%
BCM
12
Bridgeway Capital Management
Texas
$242K – – –
Geode Capital Management
13
Geode Capital Management
Massachusetts
$211K – – –
NW
14
NewEdge Wealth
Pennsylvania
$192K – – –
DIM
15
DC Investments Management
Virginia
$74.7K – – –
State Street
16
State Street
Massachusetts
$50.4K +$25.2K +10,600 +79%
PFMU
17
Privium Fund Management (UK)
United Kingdom
$41K – – –
CC
18
Cannell Capital
Wyoming
$30.8K – – –
Northern Trust
19
Northern Trust
Illinois
$29.7K +$6.9K +2,905 +26%
LPL Financial
20
LPL Financial
California
$25.2K -$11.9K -5,000 -29%
Renaissance Technologies
21
Renaissance Technologies
New York
$24K +$3.8K +1,600 +16%
WPW
22
Waldron Private Wealth
Pennsylvania
$21K +$23.7K +10,000 New
TRCT
23
Tower Research Capital (TRC)
New York
$9K -$5K -2,108 -34%
UBS Group
24
UBS Group
Switzerland
$6.8K +$5.32K +2,240 +224%
ACA
25
Atlas Capital Advisors
Wyoming
$1.88K – – –
1
2

TCRX Hedge Fund Activity: Q1 2023 in Review

28 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q1 2023, worth a combined $20.3M — up 37% from $14.8M a quarter earlier.

Fund positioning in TCRX was balanced in Q1 2023: 3 funds opened new positions, 3 closed out, 9 added to existing stakes and 3 trimmed.

The largest buyer was Simplify Asset Management, opening a new position worth an estimated $1.3M. The largest seller was Tang Capital Management, exiting entirely with an estimated $798K sold.

  • 28 institutional investors held TScan Therapeutics (TCRX) as of Q1 2023, unchanged from Q4 2022.
  • Funds reported $20.3M of TScan Therapeutics stock for Q1 2023, up 37% quarter-over-quarter.
  • 3 funds opened new TScan Therapeutics positions in Q1 2023 and 3 closed out, a net change of 0 holders.
  • The largest TScan Therapeutics buyer in Q1 2023 was Simplify Asset Management, an estimated $1.3M added.
  • The largest TScan Therapeutics seller in Q1 2023 was Tang Capital Management, an estimated $798K sold.

Based on aggregated 13F filings for Q1 2023.